| 摘要 |
Analogues of FGF21 carrying a modifying, substituted ethylene or benzyl group can be used for treatment or prevention of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD). |
| 申请人 |
NOVO NORDISK A/S |
发明人 |
TAGMOSE, TINA MOELLER;GARIBAY, PATRICK WILLIAM;ZHANG, XUJIA;THOEGERSEN, HENNING;NIELSEN, PETER KRESTEN;ANDERSEN, BIRGITTE;WANG, JISHU;BAK-JENSEN, KRISTIAN SASS;WOELDIKE, HELLE FABRICIUS |
